|1.||Garey, Kevin W: 3 articles (01/2013 - 05/2010)|
|2.||Macarthur, Rodger D: 2 articles (11/2013 - 09/2013)|
|3.||Crutchley, Rustin D: 2 articles (01/2013 - 05/2010)|
|4.||Cottreau, Jessica: 2 articles (01/2013 - 02/2012)|
|5.||Divers, T J: 1 article (11/2015)|
|6.||Stokol, T: 1 article (11/2015)|
|7.||Bicalho, R C: 1 article (11/2015)|
|8.||Chin-Beckford, Nafeesa: 1 article (11/2015)|
|9.||Teixeira, A G V: 1 article (11/2015)|
|10.||Castro, Jose G: 1 article (11/2015)|
11/01/2013 - "In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided significant improvement in diarrhea with a favorable safety profile."
11/01/2015 - "More research is needed to test the efficacy of enteric-coated crofelemer on incidence and severity of secretory diarrhea on calves under natural challenge conditions. "
05/01/2010 - "Crofelemer possesses a novel mechanism of action that shows promise in treating secretory diarrhea of several etiologies. "
11/01/2013 - "Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study."
11/01/2015 - "This review aims to provide a concise evaluation of a newly approved medication (crofelemer) that has a novel mechanism of action and has received approval for the symptomatic relief of non-infectious diarrhea in adult patients with HIV on anti-retroviral therapy. "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
04/01/2013 - "The efficacy of crofelemer has been investigated in patients with HIV-associated diarrhea, diarrhea of various infectious etiologies, as well as diarrhea-predominant irritable bowel syndrome. "
05/01/2010 - "In a third trial, crofelemer did not offer a significant benefit in improving stool consistency after 12 weeks of treatment in patients with diarrhea-predominant irritable bowel syndrome. "
01/01/2008 - "This double-blind, randomized, placebo-controlled trial evaluated the effects of 3 dose levels of crofelemer in patients with diarrhea-predominant irritable bowel syndrome (D-IBS). "
01/01/2008 - "Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients."
|3.||Acquired Immunodeficiency Syndrome (AIDS)
07/01/2013 - "Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy."
01/01/2013 - "Results from the ADVENT trial showed that crofelemer reduced symptoms of secretory diarrhea in HIV/AIDS patients. "
11/01/2015 - "Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy."
04/01/2013 - "Crofelemer was approved by the FDA in December 2012 to treat diarrhea in HIV/AIDS patients on antiretroviral therapy. "
01/01/2013 - "More recently, crofelemer was approved by the US Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. "
01/01/2013 - "The efficacy and safety of crofelemer has been evaluated in clinical trials for various types of secretory diarrhea, including cholera-related and acute infectious diarrhea. "
05/01/2010 - "Preliminary studies also show that crofelemer may reduce watery stool output in patients with infectious diarrhea such as cholera. "
02/01/2012 - "In studies in diarrheal illness associated with primarily a secretory component, such as cholera, travelers' diarrhea and acute infectious diarrhea, crofelemer has shown improvements in stool consistency and duration of symptoms. "
|4.||Chloride Channels (Chloride Channel)
|5.||Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)
|1.||Highly Active Antiretroviral Therapy (HAART)